A cell-based screen for drugs to treat Huntington's disease.
We have developed a medium-throughput cell-based assay to screen drugs for Huntington's disease (HD). The assay measures the ability of drugs to protect cultured neuronal (PC12) cells from death caused by an expanded polyglutamine (poly Q) form of huntingtin exon 1. Using this assay, we have blindly screened a library of 1040 compounds compiled by the NINDS: the NIH Custom Collection (NCC). Each compound was tested at five concentrations for its ability to protect cells against huntingtin-induced cell death as well as for its toxicity. Of the compounds tested, 18 prevented cell death completely, and 51 partially. Some of these also exhibited toxicity at higher doses. The majority of drugs (81%) were ineffective. Caspase inhibitors and cannabinoids showed reproducible protection in our assay. We believe these compounds, and others in our hit list, are appealing candidates for further investigation. Additionally, this assay is amenable to scaling up to screen additional compounds for treating Huntington's disease.
Aiken
Charity T
CT
Departments of Physiological Science and Neurology, Brain Research Institute, University of California, Los Angeles, CA 90095, USA.
Tobin
Allan J
AJ
Schweitzer
Erik S
ES
D000818:Animals; D001593:Benzyl Compounds / Q000494:pharmacology; D002186:Cannabinoids / Q000494:pharmacology; D061945:Caspase Inhibitors; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006816:Huntington Disease / Q000188:drug therapy*; D006845:Hydrocarbons, Fluorinated / Q000494:pharmacology; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D016716:PC12 Cells; D051381:Rats; D013194:Staining and Labeling
D001593:Benzyl Compounds; C476029:Boc-D-FMK; D002186:Cannabinoids; D061945:Caspase Inhibitors; D015853:Cysteine Proteinase Inhibitors; D006845:Hydrocarbons, Fluorinated; D007770:L-Lactate Dehydrogenase